FR2978662A1 - Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie - Google Patents

Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie Download PDF

Info

Publication number
FR2978662A1
FR2978662A1 FR1157040A FR1157040A FR2978662A1 FR 2978662 A1 FR2978662 A1 FR 2978662A1 FR 1157040 A FR1157040 A FR 1157040A FR 1157040 A FR1157040 A FR 1157040A FR 2978662 A1 FR2978662 A1 FR 2978662A1
Authority
FR
France
Prior art keywords
ombrabulin
cisplatin
ave8062
administration
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR1157040A
Other languages
English (en)
French (fr)
Inventor
Chantal Carrez
Celine Clemenson
Eric Deutsch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Priority to FR1157040A priority Critical patent/FR2978662A1/fr
Priority to PCT/IB2012/053879 priority patent/WO2013018017A1/en
Priority to ARP120102781A priority patent/AR087392A1/es
Priority to TW101127825A priority patent/TW201313225A/zh
Priority to UY0001034232A priority patent/UY34232A/es
Publication of FR2978662A1 publication Critical patent/FR2978662A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR1157040A 2011-08-01 2011-08-01 Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie Withdrawn FR2978662A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR1157040A FR2978662A1 (fr) 2011-08-01 2011-08-01 Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie
PCT/IB2012/053879 WO2013018017A1 (en) 2011-08-01 2012-07-30 Antitumour combination comprising ombrabulin and cisplatin, associated with radiotherapy
ARP120102781A AR087392A1 (es) 2011-08-01 2012-07-31 Combinacion antitumoral que comprende ombrabulina y cisplatino, asociada a radioterapia
TW101127825A TW201313225A (zh) 2011-08-01 2012-08-01 與放射線治療關聯之包含奧瑞布林（ｏｍｂｒａｂｕｌｉｎ）及順鉑（ｃｉｓｐｌａｔｉｎ）之抗腫瘤組合
UY0001034232A UY34232A (es) 2011-08-01 2012-08-01 Combinación antitumoral que comprende ombrabulina y cisplatino,asociada a radioterapia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1157040A FR2978662A1 (fr) 2011-08-01 2011-08-01 Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie

Publications (1)

Publication Number Publication Date
FR2978662A1 true FR2978662A1 (fr) 2013-02-08

Family

ID=46832546

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1157040A Withdrawn FR2978662A1 (fr) 2011-08-01 2011-08-01 Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie

Country Status (5)

Country Link
AR (1) AR087392A1 (zh)
FR (1) FR2978662A1 (zh)
TW (1) TW201313225A (zh)
UY (1) UY34232A (zh)
WO (1) WO2013018017A1 (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1068870A1 (en) * 1998-04-03 2001-01-17 Ajinomoto Co., Inc. Antitumor agents
WO2005110426A1 (en) * 2004-05-14 2005-11-24 Angiogene Pharmaceuticals Ltd Vascular damaging agents for administration as an intravenous infusion

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4259598A (en) 1979-12-20 1981-03-31 General Electric Company Charge transfer signal processing apparatus transversal filter
US20020183266A1 (en) 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
DE60238408D1 (de) 2001-06-25 2011-01-05 Ajinomoto Kk Antitumorale mittel
FR2838437B1 (fr) 2002-04-11 2004-06-04 Aventis Pharma Sa Procedes de preparation de combretastatines
FR2895258B1 (fr) 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
WO2009103076A1 (en) 2008-02-15 2009-08-20 Oxigene, Inc. Methods and compositions for enhancing the efficacy of rtk inhibitors
FR2945210B1 (fr) 2009-05-07 2011-07-01 Sanofi Aventis Combinaison antitumorale comprenant l'ave8062 et le sorafenib

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1068870A1 (en) * 1998-04-03 2001-01-17 Ajinomoto Co., Inc. Antitumor agents
WO2005110426A1 (en) * 2004-05-14 2005-11-24 Angiogene Pharmaceuticals Ltd Vascular damaging agents for administration as an intravenous infusion

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARCU LOREDANA ET AL: "Cisplatin and radiotherapy in the treatment of locally advanced head and neck cancer--a review of their cooperation.", ACTA ONCOLOGICA (STOCKHOLM, SWEDEN) 2003 LNKD- PUBMED:12899503, vol. 42, no. 4, 2003, pages 315 - 325, XP009161333, ISSN: 0284-186X *
PATTERSON ET AL: "Vascular Damaging Agents", CLINICAL ONCOLOGY, W.B. SAUNDERS, AMSTERDAM, NL, vol. 19, no. 6, 2 July 2007 (2007-07-02), pages 443 - 456, XP022137687, ISSN: 0936-6555, DOI: 10.1016/J.CLON.2007.03.014 *

Also Published As

Publication number Publication date
TW201313225A (zh) 2013-04-01
WO2013018017A1 (en) 2013-02-07
AR087392A1 (es) 2014-03-19
UY34232A (es) 2013-02-28

Similar Documents

Publication Publication Date Title
US20110082101A1 (en) Combinations comprising epothilones and anti-metabolites
EP2427185A1 (fr) Combinaison antitumorale comprenant l'ave8062 et le sorafenib
ES2625492T3 (es) Combinación terapéutica que comprende un inhibidor de Cdc7 y un agente antineoplásico
WO2007077309A1 (fr) Combinaison comprenant de la combretastatine et des agents anticancereux
TWI441639B (zh) 用於治療卵巢癌之包含紫杉醇之組合
JP2009536956A (ja) 抗癌治療法
WO2009024667A2 (fr) Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
CN111902147A (zh) 五氮杂大环状环配合物和基于铂的抗癌剂的组合癌症治疗
WO2023133371A2 (en) Compositions and methods for treating cancer or preventing, inhibiting or reducing risk of metastasis of a cancer
JP2018516936A5 (zh)
JP2004510734A (ja) ディスタマイシン誘導体を含む抗腫瘍療法
CA2672716C (fr) Nouvelle utilisation therapeutique pour le traitement des leucemies
JP2016503035A (ja) 肝疾患または肝障害の治療のための使用および方法
Kawahara et al. Caffeine dose-dependently potentiates the antitumor effect of cisplatin on osteosarcomas
FR2968557A1 (fr) Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab
FR2978662A1 (fr) Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie
FR2978663A1 (fr) Combinaison antitumorale comprenant l'ombrabuline et le cetuximab, associee a la radiotherapie
CA3157656A1 (fr) Utilisation de nictotinamide mononucleotide (nmn) pour la prevention et/ou le traitement de la polyarthrite rhumatoide et compositions correspondantes
JP2011513274A (ja) モルホリニルアントラサイクリン誘導体および脱メチル化剤を含む、抗腫瘍性組合せ
KR20210039413A (ko) 암의 치료를 위한 병용 요법
JP2005502690A (ja) 癌治療についての４−ピリジルメチルフタラジンの使用
JP2023511072A (ja) 癌の治療のための組み合わせおよびその用途
EP4106739A1 (en) Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue
JP2016017059A (ja) 抗腫瘍性プロドラッグを含む組成物
US20220339162A1 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating desmoid tumors

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20140430